Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.
| Condition | Intervention | Phase |
|---|---|---|
|
Cognitive Deficits in Schizophrenia |
Drug: ABT-126 Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) |
- Cognition: MCCB [ Time Frame: Measurements from screening period through 12-week treatment period ] [ Designated as safety issue: No ]
- Functioning: UPSA-2 [ Time Frame: Measurements from screening period through 12-week treatment period ] [ Designated as safety issue: No ]
- Cognition: CANTAB [ Time Frame: Measurements from screening period through 12-week treatment period ] [ Designated as safety issue: No ]
- Symptom Severity: PANSS, NSA-16, CGI-S [ Time Frame: Measurements from screening period through 12-week treatment period ] [ Designated as safety issue: No ]
| Enrollment: | 207 |
| Study Start Date: | March 2010 |
| Study Completion Date: | September 2011 |
| Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: ABT-126 Dose 1 |
Drug: ABT-126
ABT-126 Dose 1, ABT-126 Dose 2
|
| Experimental: ABT-126 Dose 2 |
Drug: ABT-126
ABT-126 Dose 1, ABT-126 Dose 2
|
| Placebo Comparator: Sugar Pill |
Drug: Placebo
Placebo
|
Detailed Description:
This is a Phase 2 study designed to evaluate the efficacy and safety of ABT-126 in approximately 210 adults with schizophrenia. Subjects will be randomized to one of three treatment groups (ABT-126 Dose 1, ABT-126 Dose 2 or placebo) for a 12-week Treatment Period. The purpose of this research study is to find out whether ABT-126 compared to placebo can improve cognition and what side effects ABT-126 may cause. Cognition is the way a person thinks, and it includes abilities like paying attention, focusing, remembering things, and solving problems. Acronyms listed in the Outcomes and/or Eligibility sections for this study are defined below: • MCCB: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery • UPSA-2: University of California at San Diego (UCSD) Performance-Based Skills Assessment-2 • CANTAB: Cambridge Neuropsychological Test Automated Battery • PANSS: Positive and Negative Syndrome Scale • NSA-16: Negative Symptom Assessment-16 • CGI-S: Clinical Global Impression - Severity
Eligibility| Ages Eligible for Study: | 20 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
- Has current DSM-IV-TR diagnosis of schizophrenia confirmed by the Mini-International Neuropsychiatric Interview.
- Is clinically stable while receiving antipsychotic therapy with one or two atypical antipsychotic medications: lack of hospitalizations from 4 months of Initial Screening Visit; taking same antipsychotic medication(s) for at least 8 weeks prior to the Day -1 visit; core positive symptoms of PANSS no worse than moderate in severity throughout Screening Period of at least 4 weeks.
- Has been diagnosed with or treated for schizophrenia for at least 2 years prior to Initial Screening Visit.
- Has had continuity in psychiatric care (e.g., mental health system, clinic or physician) for at least 6 months prior to Initial Screening Visit.
- Has an identified responsible contact person (e.g., family member, social worker, case worker, or nurse) that can provide support to the subject and ensure compliance with protocol requirements.
Exclusion Criteria
- Has valid current or past diagnosis of schizoaffective disorder, bipolar disorder, manic episode, dementia, posttraumatic stress disorder, obsessive compulsive disorder, or a current major depressive episode.
- Has history of substance abuse (excluding nicotine or tobacco products) or alcohol abuse within 6 months prior to Screening Visit; has a substance dependence disorder (excluding nicotine or tobacco products) that has not been remitted for at least 1 year prior to Initial Screening Visit.
- Is taking any medication for extrapyramidal symptoms at any time from the Initial Screening Visit until the Day -1 Visit.
- Is taking any antidepressant that is excluded, including tricyclic antidepressants and monoamine oxidase inhibitors, at any time from 8 weeks prior to the Day -1 Visit.
- Has significant suicidal ideation at Initial Screening Visit.
- Has had a suicide attempt within 1 year prior to the Day -1 Visit.
- Has participated in another trial utilizing the MATRICS Consensus Cognitive Battery (MCCB) or UCSD Performance-Based Skills Assessment (UPSA) (any version) within 6 months prior to Initial Screening Visit.
- Is currently enrolled in any form of cognitive remediation training.
Contacts and Locations| United States, California | |
| Site Reference ID/Investigator# 26267 | |
| Cerritos, California, United States, 90703 | |
| Site Reference ID/Investigator# 45320 | |
| Costa Mesa, California, United States, 92626 | |
| Site Reference ID/Investigator# 27068 | |
| Escondido, California, United States, 92025 | |
| Site Reference ID/Investigator# 52568 | |
| Garden Grove, California, United States, 92845 | |
| Site Reference ID/Investigator# 26266 | |
| Granada Hills, California, United States, 91344 | |
| Site Reference ID/Investigator# 26388 | |
| Oceanside, California, United States, 92056 | |
| Site Reference ID/Investigator# 45315 | |
| San Bernardino, California, United States, 92408 | |
| Site Reference ID/Investigator# 26271 | |
| San Diego, California, United States, 92102 | |
| Site Reference ID/Investigator# 45314 | |
| Santa Ana, California, United States, 92705 | |
| Site Reference ID/Investigator# 27045 | |
| Santa Ana, California, United States, 92701 | |
| Site Reference ID/Investigator# 26264 | |
| Torrance, California, United States, 90502 | |
| United States, Florida | |
| Site Reference ID/Investigator# 27072 | |
| Tampa, Florida, United States, 33613 | |
| United States, Kansas | |
| Site Reference ID/Investigator# 27043 | |
| Wichita, Kansas, United States, 67214 | |
| United States, Louisiana | |
| Site Reference ID/Investigator# 26395 | |
| Lake Charles, Louisiana, United States, 70629 | |
| United States, Missouri | |
| Site Reference ID/Investigator# 26268 | |
| St. Louis, Missouri, United States, 63118 | |
| United States, New York | |
| Site Reference ID/Investigator# 26392 | |
| Fresh Meadows, New York, United States, 11366 | |
| Site Reference ID/Investigator# 27073 | |
| New York, New York, United States, 10065 | |
| Site Reference ID/Investigator# 26262 | |
| Rochester, New York, United States, 14618 | |
| United States, Ohio | |
| Site Reference ID/Investigator# 27071 | |
| Beachwood, Ohio, United States, 44122 | |
| United States, Pennsylvania | |
| Site Reference ID/Investigator# 36020 | |
| Media, Pennsylvania, United States, 19063 | |
| Site Reference ID/Investigator# 28063 | |
| Norristown, Pennsylvania, United States, 19401 | |
| Site Reference ID/Investigator# 27070 | |
| Sellersville, Pennsylvania, United States, 18960 | |
| United States, Texas | |
| Site Reference ID/Investigator# 27069 | |
| Dallas, Texas, United States, 75243 | |
| Study Director: | George Haig, PharmD | AbbVie |
More Information
No publications provided
| Responsible Party: | AbbVie ( AbbVie (prior sponsor, Abbott) ) |
| ClinicalTrials.gov Identifier: | NCT01095562 History of Changes |
| Other Study ID Numbers: | M10-854 |
| Study First Received: | March 26, 2010 |
| Last Updated: | January 2, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders |
ClinicalTrials.gov processed this record on May 22, 2013